Khalil G. Saikali

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 329 citations

Cardiomyopathy, Heart Failure, Omecamtiv Mecarbil +10

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Robert Provenzano, Anatole Besarab, Chao Sun et al. · Clinical Journal of the American Society of Nephrology · 2016 · 290 citations · Full text

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali et al. · The Lancet · 2011 · 260 citations

Cardiac Muscle, Cardiomyopathy, Omecamtiv Mecarbil +12

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Robert Provenzano, Anatole Besarab, Steven Charles Wright et al. · American Journal of Kidney Diseases · 2016 · 254 citations · Full text

Roxadustat (FG-4592)

Anatole Besarab, Igor Motylev, Evgeny Shutov et al. · Journal of the American Society of Nephrology · 2015 · 246 citations · Full text

Anemia, Hemodialysis, Urology +15